Y Graic
Overview
Explore the profile of Y Graic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanzen C, de Lafontan B, Missohou F, Veyret C, Laberge S, Picquenot J, et al.
Cancer Radiother
. 2004 Sep;
8(4):217-21.
PMID: 15450514
Margin status is regarded as a major prognostic factor for local recurrence after breast conservative treatment. Margin definition in the literature is not always clear and precise. The impact on...
2.
Cutuli B, Borel C, Dhermain F, Magrini S, Wasserman T, Bogart J, et al.
Radiother Oncol
. 2001 May;
59(3):247-55.
PMID: 11369065
Purpose: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods. Materials And Methods: In a retrospective...
3.
Cutuli B, Dhermain F, Borel C, de Larochefordiere A, Graic Y, de Lafontan B, et al.
Eur J Cancer
. 1998 Jun;
33(14):2315-20.
PMID: 9616274
In a retrospective multicentric analysis, 63 women treated between 1941 to 1988 for Hodgkin's disease (HD) subsequently developed 76 breast cancers (BC). The median age at diagnosis of HD was...
4.
Cutuli B, De La Rochefordiere A, Dhermain F, Borel C, Graic Y, de Lafontan B, et al.
Cancer Radiother
. 1997 Jan;
1(4):300-6.
PMID: 9435820
Purpose: Though Hodgkin's disease (HD) is one of the malignancies in which considerable progress has been made, long-term side effects have been observed, second primary cancer being the most significant....
5.
Cutuli B, Dilhuydy J, de Lafontan B, Berlie J, Lacroze M, Lesaunier F, et al.
Eur J Cancer
. 1997 Jan;
33(1):35-8.
PMID: 9071896
From 1970 to 1992, 31 pure ductal carcinoma in situ (DCIS) of the male breast treated in 19 French Regional Cancer Centres were reviewed. They represent 5% of all breast...
6.
Cutuli B, Lacroze M, Dilhuydy J, Velten M, de Lafontan B, Marchal C, et al.
Eur J Cancer
. 1995 Nov;
31A(12):1960-4.
PMID: 8562148
From 1960 to 1986, 397 cases of non-metastatic male breast cancer (MBC) treated in 14 French regional cancer centres were reviewed. The median age was 64 years (range 25-93). TNM...
7.
Azagury M, Chevallier B, Atlan D, Graic Y, Dayot J, Thomine E
Am J Clin Oncol
. 1993 Apr;
16(2):102-4.
PMID: 7680840
A complete response with combination chemotherapy was obtained in a patient with metastatic Merkel cell carcinoma. This complete response lasted 15 months. This case report demonstrates the chemosensitivity of this...
8.
Chevallier B, Bastit P, Graic Y, Menard J, Dauce J, Julien J, et al.
Br J Cancer
. 1993 Mar;
67(3):594-601.
PMID: 8439510
One hundred and seventy-eight patients with non metastatic inflammatory breast cancer (IBC) have been treated at the Centre H. Becquerel. Median follow up is 67 months (6-178). Every patient received...
9.
Basuyau J, Brunelle P, Charrot P, Chevallier B, Delapierre F, Graic Y, et al.
Bull Cancer
. 1993 Mar;
80(3):213-8.
PMID: 8173173
This retrospective study shows the advantage of the CA 15.3 assay for the early detection of relapse in breast cancer. It involved 473 women with invasive canalar carcinoma who had...
10.
Cutuli B, Lacroze M, Dilhuydy J, Florentz P, Velten M, Allavena C, et al.
Bull Cancer
. 1992 Jan;
79(7):689-96.
PMID: 1467595
Male breast cancer represents about only 1% of all breast cancers. We have analysed a retrospective, multicentric series of 404 patients, initially non-metastatic, with mean age of 63 years. The...